MAIA Biotechnology (MAIA) Net Equity Issued and Repurchased (2021 - 2025)
MAIA Biotechnology (MAIA) posted quarterly Net Equity Issued and Repurchased of $1.5 million for Q1 2025, up 104.1% year-over-year from $745251.0 in Q1 2024, and up 415.93% quarter-over-quarter from -$481460.0 in Q4 2024.
MAIA Biotechnology (MAIA) Net Equity Issued and Repurchased (2021 - 2025) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $1.5 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Net Equity Issued and Repurchased rose 104.1% year-over-year to $1.5 million; the TTM figure through Mar 2025 stood at $3.2 million (up 280.37% YoY), while the FY2024 annual figure was $2.4 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased improved to $1.5 million in Q1 2025 per MAIA's latest filing, from -$481460.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $7.1 million in Q2 2024 and bottomed at -$4.9 million in Q3 2024.
- Historically, Net Equity Issued and Repurchased has averaged $851236.0 across 4 years, with a median of $560626.0 in 2021.
- On a YoY basis, Net Equity Issued and Repurchased climbed as much as 104.1% in 2025 and fell as far as 104.1% in 2025.
- MAIA Biotechnology's Net Equity Issued and Repurchased stood at $376001.0 in 2021, then slumped by 73.4% to $99999.0 in 2022, then slumped by 581.46% to -$481460.0 in 2024, then jumped by 415.93% to $1.5 million in 2025.
- Business Quant data shows MAIA's Net Equity Issued and Repurchased at $1.5 million in Q1 2025, -$481460.0 in Q4 2024, and -$4.9 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 1.52 Mn |
| Mar 31, 2025 | 1.52 Mn |
| Dec 31, 2024 | -481,460.00 |
| Dec 31, 2024 | -481,460.00 |
| Sep 30, 2024 | -4.94 Mn |
| Sep 30, 2024 | -4.94 Mn |
| Jun 30, 2024 | 7.12 Mn |
| Jun 30, 2024 | 7.12 Mn |
| Mar 31, 2024 | 745,251.00 |
| Mar 31, 2024 | 745,251.00 |
| Jun 30, 2022 | 99,999.00 |
| Jun 30, 2022 | 99,999.00 |
| Mar 31, 2022 | 2.37 Mn |
| Mar 31, 2022 | 2.37 Mn |
| Dec 31, 2021 | 376,001.00 |
| Dec 31, 2021 | 376,001.00 |